ELVN - Wall Street Estimates - Enliven Therapeutics, Inc.

Healthcare - Biotechnology - NASDAQ - US

$ 21.47

-2.36 %

$ 1.05 B

Market Cap

-11.36

P/E

Price Target Average

68.84%

Revenue Forecast Estimate

-0.00%

EBIT Estimate

25.99%

Net Income Estimate

--13.74%

WALL STREET ESTIMATES

Wall Street Analysts Price Targets Enliven Therapeutics, Inc.

Wall Street analysts predict an average 1-year price target for ELVN of $36.2 , with forecasts ranging from a low of $32 to a high of $40 .

ELVN Lowest Price Target Wall Street Target

32 USD 49.05%

ELVN Average Price Target Wall Street Target

36.2 USD 68.84%

ELVN Highest Price Target Wall Street Target

40 USD 86.31%

REVENUE FORECAST

EBIT FORECAST

NET INCOME FORECAST

Free